Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

Abstract Introduction Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). Methods A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 mg once daily for 12 weeks on primary safety and pharma...

Full description

Bibliographic Details
Main Authors: Fernando L. Pagan, Yasar Torres‐Yaghi, Michaeline L. Hebron, Barbara Wilmarth, R. Scott Turner, Sara Matar, Dalila Ferrante, Jaeil Ahn, Charbel Moussa
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Abelson
activities of daily living
alpha‐synuclein
dementia with Lewy bodies
dopamine
Online Access:https://doi.org/10.1002/trc2.12296

Similar Items

Similar Items